$1.5 Million Cleveland Foundation Grant Continues to Build Proteomics Infrastructure at Case Western Reserve University
News May 11, 2009
The Cleveland Foundation has made a $1.5 million grant to the Case Western Reserve University School of Medicine to support second-phase funding for the Center for Proteomics and Bioinformatics. The grant will allow the school to continue to build strength in a field that is a cornerstone of the future of medical care-proteomics, the study of proteins and their changes in disease.
"The Cleveland Foundation is pleased to provide a second phase of support for the Center for Proteomics and Bioinformatics at the School of Medicine. The Center has demonstrated real impact to the health of individuals and to the health of the community through its advancement of new diagnostics and therapies. It is an important driver in the continued growth of Cleveland’s leadership in the biotech sector," said Robert Eckardt, Dr. PH, Senior Vice President of the Cleveland Foundation.
This funding allows the university to advance its leadership role in developing customized technologies and research that will make a significant impact on human health. The grant further lays the groundwork for attracting biotech start-up companies to the area.
The grant will also allow the center to develop its program in proteomic medicine. The purpose of this program is to identify and develop novel diagnostic tests to help in the management of chronic diseases. By combining a solid understanding of genetic and proteomic data from patients, investigators will be able to determine which individuals and groups are more susceptible to certain conditions. Ultimately, it will allow them to develop appropriate treatment and prevention plans based on individual makeup.
"This grant underscores the remarkable progress made by Mark Chance, Ph.D., director of the Center for Proteomics and Bioinformatics, and his team," said Pamela B. Davis, M.D., Ph.D., dean of the School of Medicine. "Their research in protein modifications is a key component of our efforts to enhance the personalization of medical treatments and to enhance diagnostic capabilities. The continued support of the Cleveland Foundation for proteomics research will allow us to further build upon our strengths as we usher in a new era of treatment and prevention."
As one of the largest cumulative donors to Case Western Reserve, the Cleveland Foundation consistently partners with the university on projects that significantly improve the quality of life in our community. In 2005, the foundation’s $5 million grant, one of its largest awards ever, launched the Center for Proteomics and Bioinformatics and provided support for research in immunobiology.
"We are pleased that the Cleveland Foundation has once again recognized the potential of this center to save and enhance people’s lives," said Case Western Reserve President Barbara R. Snyder. "The foundation’s support is critical to our efforts to translate fundamental research to treatments, which in turn help drives economic development of our region."
Algorithm Speeds Up Medical Image Analysis 1000 TimesNews
Medical image registration is a common technique that involves overlaying two images, such as magnetic resonance imaging (MRI) scans, to compare and analyze anatomical differences in great detail. Researchers have described a machine-learning algorithm that can register brain scans and other 3-D images more than 1,000 times more quickly using novel learning techniques.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE